Suspected cancer: recognition and referral<\/em>, in June 2015, to ensure that it reflects latest evidence and can continue to support general practitioners (GPs) to identify patients, including children and young people and urgently refer them as appropriate. NICE noted that 5,000 more lives could be saved each year in England if GPs followed the new guideline, which encourage GPs to think of cancer sooner and lower the referral threshold.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4080", "label" : {"_value" : "Biography information for David Mowat"}
}
, "answeringMemberConstituency" : {"_value" : "Warrington South"}
, "answeringMemberPrinted" : {"_value" : "David Mowat"}
, "dateOfAnswer" : {"_value" : "2016-10-17", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2016-10-17T16:17:50.467Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2016-10-07", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Pancreatic Cancer: Mortality Rates"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what steps he is taking to reduce mortality rates for people diagnosed with pancreatic cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4443", "label" : {"_value" : "Biography information for Carol Monaghan"}
}
, "tablingMemberConstituency" : {"_value" : "Glasgow North West"}
, "tablingMemberPrinted" : [{"_value" : "Carol Monaghan"}
], "uin" : "47270"}
, {"_about" : "http://data.parliament.uk/resources/431696", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/431696/answer", "answerText" : {"_value" : "The Department has conducted no such research. Current arrangements already allow off-patent drugs to be prescribed for new purposes where this is the most appropriate clinical treatment course for a patient. Prescribing decisions are a matter for the clinical judgement of the prescriber concerned.<\/p>
"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-12-01", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-12-01T16:49:32.557Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-11-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Prescription Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what research his Department has conducted on the disincentives to prescribing off-patent repurposed drugs.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4443", "label" : {"_value" : "Biography information for Carol Monaghan"}
}
, "tablingMemberConstituency" : {"_value" : "Glasgow North West"}
, "tablingMemberPrinted" : [{"_value" : "Carol Monaghan"}
], "uin" : "17150"}
, {"_about" : "http://data.parliament.uk/resources/431700", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/431700/answer", "answerText" : {"_value" : "
The current legal framework allows a clinician to prescribe drugs outside their licensed indication where that will best meet the clinical needs of their patient. This clinical freedom is crucial in delivering appropriate healthcare to groups of patients for whom medicines have not historically been licensed, e.g. children. It is also helpful in enabling prescribers to quickly pick up and apply new evidence that will help patients with particular clinical needs. The Off-Patent Drugs Bill would introduce a legal duty to apply for a licence for off-patent drugs where evidence of effectiveness for a new indication becomes available. This will create an expectation that only licensed uses of drugs are acceptable and therefore that off-label use is not appropriate. This would cause unnecessary delays in patients getting the medicines they need by slowing the rapid uptake of new evidence in clinical practice. This is why we believe the proposed legislation could potentially be harmful.<\/p>
"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-12-01", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-12-01T16:45:34.637Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-11-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Off-patent Drugs Bill"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, pursuant to the contribution of 6 November 2015 by the Minister for Community and Social Care, Official Report, column 1307, what the evidential basis is for his statement that the provisions of the Off-patent Drugs Bill would be potentially harmful.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4443", "label" : {"_value" : "Biography information for Carol Monaghan"}
}
, "tablingMemberConstituency" : {"_value" : "Glasgow North West"}
, "tablingMemberPrinted" : [{"_value" : "Carol Monaghan"}
], "uin" : "17208"}
, {"_about" : "http://data.parliament.uk/resources/428555", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/428555/answer", "answerText" : {"_value" : "
Clinicians can already prescribe off-patent drugs off-label on clinical grounds if they judge this is the right thing to do to meet the individual clinical needs of their patients.<\/p>
The Government is keen to accelerate the adoption of innovative medicines and increase the innovative use of existing medicines where the evidence reports clinical benefits and cost effectiveness to patients. To that end, we are seeking a number of initiatives to provide innovation but whilst supporting the aims of the Private Member\u2019s Bill on this subject, we do not believe the proposed mechanism is either practicable and desirable.<\/p>
We are working with NHS England, the National Institute for Health and Care Excellence, the General Medical Council and the Medicines and Health products Regulatory Agency to ensure that there is better information available to support clinicians who wish to prescribe off-patent drugs for off-label indications, and to ensure that new evidence is picked up more quickly and reliably and translated into clinical practice and can be fed through into licensing applications.<\/p>
A huge amount of work is also going on in the Accelerated Access Review which will support the \u201cpull\u201d of innovation through to clinical practice.<\/p>
As part of the debate on the Access to Medical Treatments Bill, we are working with officials in the Department, the Medicines and Healthcare products Regulatory Agency, and the Health and Social Care Information Centre to see how the power in the Bill, if it were to pass, could address the lack of provision of information on new uses for existing medicines via the power to create a database of innovations in order to support evidence-based prescribing.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-11-17", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "902127"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-11-17T17:20:22.137Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-11-10", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Drugs: Licensing"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what plans he has to improve the availability of off-patent drugs for novel uses through non-legislative measures.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4443", "label" : {"_value" : "Biography information for Carol Monaghan"}
}
, "tablingMemberConstituency" : {"_value" : "Glasgow North West"}
, "tablingMemberPrinted" : [{"_value" : "Carol Monaghan"}
], "uin" : "902130"}
, {"_about" : "http://data.parliament.uk/resources/173272", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/173272/answer", "answerText" : {"_value" : "
There has been no assessment made of the effect of social care budget changes on accident and emergency (A&E) attendances. However, the Government has legislated to establish the Better Care Fund from 2015-16 to provide better integrated care. One of the conditions of the Better Care Fund is to improve the delivery of health and social care by preventing people reaching crisis point, and to reduce the quantity of non-elective admissions to acute care, which may serve to ease the pressures on A&E departments.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "answeringMemberConstituency" : {"_value" : "North Norfolk"}
, "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
, "dateOfAnswer" : {"_value" : "2015-01-13", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-01-13T15:13:07.293Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-01-07", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Accident and Emergency Departments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the effect of social care budget changes on A&E attendances.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/605", "label" : {"_value" : "Biography information for John Robertson"}
}
, "tablingMemberConstituency" : {"_value" : "Glasgow North West"}
, "tablingMemberPrinted" : [{"_value" : "John Robertson"}
], "uin" : "906970"}
, {"_about" : "http://data.parliament.uk/resources/168976", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/168976/answer", "answerText" : {"_value" : "
The United Kingdom Food Standards Agency (FSA) is working in partnership with industry to tackle Campylobacter<\/em>, exploring a range of interventions targeted at different points in the food chain to reduce contamination levels before the meat reaches the consumer. Also, in publishing the quarterly results of its UK-wide microbiological survey of Campylobacter<\/em> contamination in fresh whole chilled chickens at retail sale, the FSA is maintaining consumer awareness of the issue and encouraging retailer action.<\/p> <\/p>
<\/p>
<\/p>
The FSA has provided guidance for consumers on the safety measures that they can take to reduce their risk of spreading and contracting Campylobacter<\/em> from raw poultry in the home and this featured in its Food Safety Week campaign earlier in the year.<\/p> <\/p>
<\/p>
<\/p>
<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
}
, "answeringMemberConstituency" : {"_value" : "Battersea"}
, "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
, "dateOfAnswer" : {"_value" : "2014-12-11", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-12-11T16:19:51.7Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-12-08", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Poultry Meat"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what steps he is taking to ensure that consumers are protected from high levels of campylobacter in poultry.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/605", "label" : {"_value" : "Biography information for John Robertson"}
}
, "tablingMemberConstituency" : {"_value" : "Glasgow North West"}
, "tablingMemberPrinted" : [{"_value" : "John Robertson"}
], "uin" : "906573"}
, {"_about" : "http://data.parliament.uk/resources/79393", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/79393/answer", "answerText" : {"_value" : "
<\/p>
Prior to the establishment of the National Institute for Health Research (NIHR) in April 2006, the main part of the Department's total health research expenditure was devolved to and managed by national health service organisations. From April 2006 to March 2009, transitional research funding was allocated to these organisations at reducing levels. The organisations have accounted for their use of the allocations they have received from the Department in an annual research and development report. The reports identify total, aggregated expenditure on national priority areas but do not provide details of spend on research into specific diseases including motor neurone disease (MND).<\/p>
<\/p>
<\/p>
<\/p>
Expenditure on MND research by the NIHR from 2009-10 through research programmes, research centres and units, and research fellowships is shown in the following table.<\/p>
<\/p>
<\/p>
<\/p>
£ million<\/em><\/p> <\/p>
2009-10<\/p><\/td> | 2010-11<\/p><\/td> | 2011-12<\/p><\/td> | 2012-13<\/p><\/td> | 2013-14<\/p><\/td><\/tr> |
0.1<\/p><\/td> | 0.1<\/p><\/td> | 0.4<\/p><\/td> | 0.7<\/p><\/td> | 0.5<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> Total spend by the NIHR on MND research is higher than this because expenditure by the NIHR Clinical Research Network (CRN) on this topic cannot be disaggregated from total CRN expenditure.<\/p> <\/p> <\/p> <\/p> My Rt. hon. Friend the Secretary of State for Health (Jeremy Hunt) has had no discussions on funding for MND research with the Scottish Government Cabinet Secretary for Health and Wellbeing.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
, "dateOfAnswer" : {"_value" : "2014-09-03", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "206931"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-09-03T14:35:42.8449035Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-07-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Motor Neurone Disease"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much funding his Department has allocated to research into motor neurone disease in each of last 10 years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/605", "label" : {"_value" : "Biography information for John Robertson"}
}
, "tablingMemberConstituency" : {"_value" : "Glasgow North West"}
, "tablingMemberPrinted" : [{"_value" : "John Robertson"}
], "uin" : "206942"}
, {"_about" : "http://data.parliament.uk/resources/79398", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/79398/answer", "answerText" : {"_value" : " <\/p> Prior to the establishment of the National Institute for Health Research (NIHR) in April 2006, the main part of the Department's total health research expenditure was devolved to and managed by national health service organisations. From April 2006 to March 2009, transitional research funding was allocated to these organisations at reducing levels. The organisations have accounted for their use of the allocations they have received from the Department in an annual research and development report. The reports identify total, aggregated expenditure on national priority areas but do not provide details of spend on research into specific diseases including motor neurone disease (MND).<\/p> <\/p> <\/p> <\/p> Expenditure on MND research by the NIHR from 2009-10 through research programmes, research centres and units, and research fellowships is shown in the following table.<\/p> <\/p> <\/p> <\/p> £ million<\/em><\/p> <\/p> 2009-10<\/p><\/td> | 2010-11<\/p><\/td> | 2011-12<\/p><\/td> | 2012-13<\/p><\/td> | 2013-14<\/p><\/td><\/tr> | 0.1<\/p><\/td> | 0.1<\/p><\/td> | 0.4<\/p><\/td> | 0.7<\/p><\/td> | 0.5<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> Total spend by the NIHR on MND research is higher than this because expenditure by the NIHR Clinical Research Network (CRN) on this topic cannot be disaggregated from total CRN expenditure.<\/p> <\/p> <\/p> <\/p> My Rt. hon. Friend the Secretary of State for Health (Jeremy Hunt) has had no discussions on funding for MND research with the Scottish Government Cabinet Secretary for Health and Wellbeing.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
, "dateOfAnswer" : {"_value" : "2014-09-03", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "206942"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-09-03T14:35:42.9073579Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-07-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Motor Neurone Disease: Scotland"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what recent discussions he has had with the Cabinet Secretary for Health and Wellbeing in Scotland on funding for research into motor neurone disease.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/605", "label" : {"_value" : "Biography information for John Robertson"}
}
, "tablingMemberConstituency" : {"_value" : "Glasgow North West"}
, "tablingMemberPrinted" : [{"_value" : "John Robertson"}
], "uin" : "206931"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&answeringDeptId=17&tablingMemberConstituency=Glasgow+North+West&max-answer.dateOfAnswer=2016-10-17&max-answer.questionFirstAnswered.=2016-10-17T16%3A17%3A50.467Z", "page" : 0, "startIndex" : 1, "totalResults" : 10, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
|
|